Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

671086.pdf (1.87 MB)

Document type

Article

Version

Published version

Publication date

2017-04-25

Publication license

cc-by (c) Novohradsky, Vojtech et al., 2017
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/113562

Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1039/c7cc01946g

Abstract

A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminiscent cyclometalated iridium(III) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.

Subject

Iridi, Càncer, Somatostatina

Subject (English)

Iridium, Cancer, Somatostatin

Citation

Collections

Articles publicats en revistes (Química Inorgànica i Orgànica)

Citation

NOVOHRADSKY, Vojtech, et al. Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents. Chemical Communications. 2017. Vol. 53, num. 5523-5526. ISSN 1359-7345. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/113562

Export metadata

JSON - METS

Share record